Objective：To evaluate the effect of high-risk factors on infliximab（IFX）efficacy in patients with Crohn’s disease（CD）. Methods：Sixty-one patients with CD who received IFX treatment（09/2012-05/2019）were recruited. We performed a retrospective study comparing IFX efficacy in patients with one（group 1），two（group 2）and more than two high-risk factors（group 3）. Patients were also subdivided according to extensive intestine lesions and perianal lesions. The rate of clinical response/mucosal healing was used as evaluation index. Results：At week 2 and week 6，group 1 achieved higher clinical response rate than group 2 and group 3（P < 0.05），while the clinical response rate at week 14 and the mucosal healing rate at week 38 among groups were not significantly different. Patients without extensive intestine lesions achieved higher clinical response rate than those with extensive intestine lesions at week 2（P=0.013）and week 6（P=0.021），while the clinical response rate at week 14 and the mucosal healing rate at week 38 were not significantly different between groups with extensive intestine lesions or not（P > 0.05）. Patients with perianal lesions or not had no significant difference on the clinical response rate and mucosal healing rate after treatment（P > 0.05）. Conclusion：Patients with fewer high-risk factors may achieve clinical response earlier，but high-risk factors may not affect the final clinical response and mucosal healing rate in patients with CD.